冠状动脉钙化评分与慢性肾脏病进展
在韩国慢性肾脏病患者队列中,1936例G1-G5期未透析患者按基线Agatston冠状动脉钙化评分(CACS)分为0 AU、1-100 AU和>100 AU三组,随访8130人年期间584例(30.2%)发生主要结局。校正后CACS 1-100 AU(HR 1.29)和>100 AU(HR 1.42)均与CKD进展风险显著升高相关,CACS较高者eGFR下降速率也更大。
要点
- CACS 1-100 AU者CKD进展风险较0 AU者升高(HR 1.29,95%CI 1.04-1.61)。
- CACS >100 AU者CKD进展风险较0 AU者升高(HR 1.42,95%CI 1.10-1.82)。
- CACS每增加1个对数标准差,CKD进展风险升高(HR 1.13,95%CI 1.03-1.24)。
核心结论
- 高CACS与肾脏不良结局风险显著增加及CKD进展相关。
研究设计与样本
- 研究纳入韩国慢性肾脏病患者结局队列中1936例CKD G1-G5期未接受肾脏替代治疗的患者。
- 主要预测指标为基线Agatston CACS分类:0 AU、1-100 AU和>100 AU。
- 主要结局定义为eGFR下降≥50%或开始肾脏替代治疗的肾衰竭。
- 随访共8130人年,主要结局发生于584例(30.2%)患者。
主要发现
- 校正病因特异性风险模型显示,CACS 1-100 AU者主要结局风险较0 AU者升高(HR 1.29,95%CI 1.04-1.61)。
- CACS >100 AU者主要结局风险较0 AU者升高(HR 1.42,95%CI 1.10-1.82)。
- CACS每增加1个对数标准差,主要结局风险升高(HR 1.13,95%CI 1.03-1.24)。
- 将非致死性心血管事件作为时变协变量后,CACS 1-100 AU(HR 1.31,95%CI 1.07-1.60)和>100 AU(HR 1.46,95%CI 1.16-1.85)仍与CKD进展风险升高相关。
- CACS较高者eGFR下降速率显著更大;关联在老年患者、2型糖尿病患者及未使用抗血小板药物者中更强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An elevated coronary artery calcification score (CACS) is associated with increased cardiovascular disease risk in patients with CKD. However, the relationship between CACS and CKD progression has not been elucidated. METHODS: We studied 1936 participants with CKD (stages G1-G5 without kidney replacement therapy) enrolled in the KoreaN Cohort Study for Outcome in Patients With CKD. The main predictor was Agatston CACS categories at baseline (0 AU, 1-100 AU, and >100 AU). The primary outcome was CKD progression, defined as a ≥50% decline in eGFR or the onset of kidney failure with replacement therapy. RESULTS: During 8130 person-years of follow-up, the primary outcome occurred in 584 (30.2%) patients. In the adjusted cause-specific hazard model, CACS of 1-100 AU (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.04 to 1.61) and CACS >100 AU (HR, 1.42; 95% CI, 1.10 to 1.82) were associated with a significantly higher risk of the primary outcome. The HR associated with per 1-SD log of CACS was 1.13 (95% CI, 1.03 to 1.24). When nonfatal cardiovascular events were treated as a time-varying covariate, CACS of 1-100 AU (HR, 1.31; 95% CI, 1.07 to 1.60) and CACS >100 AU (HR, 1.46; 95% CI, 1.16 to 1.85) were also associated with a higher risk of CKD progression. The association was stronger in older patients, in those with type 2 diabetes, and in those not using antiplatelet drugs. Furthermore, patients with higher CACS had a significantly larger eGFR decline rate. CONCLUSION: Our findings suggest that a high CACS is associated with significantly increased risk of adverse kidney outcomes and CKD progression.
引用
- Yun HR, Joo YS, Kim HW, et al. Coronary Artery Calcification Score and the Progression of Chronic Kidney Disease. J Am Soc Nephrol. 2022. PMID: 35654602. doi:10.1681/ASN.2022010080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。